Exploring effective core drug patterns in primary insomnia treatment with Chinese herbal medicine: study protocol for a randomized controlled trial by Shiyan Yan et al.
TRIALS
Yan et al. Trials 2013, 14:61
http://www.trialsjournal.com/content/14/1/61STUDY PROTOCOL Open AccessExploring effective core drug patterns in primary
insomnia treatment with Chinese herbal
medicine: study protocol for a randomized
controlled trial
Shiyan Yan1, Runshun Zhang2, Xuezhong Zhou3, Peng Li1, Liyun He1* and Baoyan Liu4*Abstract
Background: Chinese herbal medicine is one of the most popular Chinese medicine (CM) therapies for primary
insomnia. One of the important characteristics of CM is that different Chinese clinicians give different prescriptions
even for the same patient. However, there must be some fixed drug patterns in every clinician’s prescriptions. This
study aims to screen the effective core drug patterns in primary insomnia treatment of three prestigious Chinese
clinicians.
Methods/design: A triple-blind, randomized, placebo-controlled, parallel-group clinical trial will be performed.
Three clinicians will diagnose and treat every eligible patient individually and independently, producing three
prescriptions from three clinicians for every patient. Patients will equally be randomized to one of four groups –
medical group A, medical group B, medical group C, or placebo group – and observed for efficacy of treatment.
The sample will include primary insomnia patients meeting DSM IV-TR criteria, Spiegel scale score >18, and age 18
to 65 years. A sequential design is employed. Interim analysis will be conducted when between 80 and 160
patients complete the study. The interim study could be stopped and treated as final if a statistically significant
difference between treatment and placebo groups can be obtained and core effective drug patterns can be
determined. Otherwise, the study continues until the maximum sample size reaches 300. Treatment of the CM
group is one of three Chinese clinicians’ prescriptions, who provide independently prescriptions based on their own
CM theory and the patient’s disease condition. Assessment will be by sleep diary and Pittsburgh sleep quality index,
and CM symptoms and signs will be measured. Primary outcome is total sleep time. Assessment will be carried out
at the washout period, weeks 1, 2, 3, and 4 and 4th week after the end of treatment. Effectiveness analysis will be
per intent to treat. A multi-dimension association rule and scale-free networks method will be used to explore the
effective core drug patterns.
Discussion: The effective core drug patterns will be found through analyzing several prestigious CM clinicians’
treatment information. Screening the effective core drug patterns from prestigious clinicians can accelerate the
development of new CM drugs.
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Insomnia is a common public health problem. Approxi-
mately one-third to one-quarter of the population in
developed nations has been reported to have sleep dis-
turbance problems to some extent in their lives and ap-
proximately 10% suffer from persistent insomnia [1].
Population-based studies suggest that about 30% of the
total population complains of sleep disruption, while ap-
proximately 10% has associated symptoms of daytime
functional impairment with the diagnosis of insomnia,
although it is unclear about the proportion among the
10% of population really suffering from chronic insom-
nia [2]. Pharmacologic therapy is the main treatment of
insomnia. However, most of the drugs prescribed for in-
somnia have some risk of overdose, tolerance and addic-
tion. Long-term use of frequently prescribed medications
(for example, benzodiazepines) can lead to habituation
and problematic withdrawal symptoms [3]. In China, most
of patients prefer to receive traditional Chinese medicine
(CM) treatment, including Chinese herbal medicine, acu-
puncture, massage and cupping [4-12]. In recent years,
the traditional CM therapy for insomnia is enjoying in-
creasing popularity in the West [5,6,13,14], reflecting
growing acceptance of such treatments even in the West.
Chinese herbal medicine is one of the most popular CM
therapies for insomnia.
However, it is a common phenomenon that the effi-
cacy of Chinese herbal drugs is related to the clinician.
In other words, the efficacy of CM varies with different
clinicians. Prestigious Chinese clinicians may therefore
have some patterns in the treatment of insomnia. In our
previous studies, we have observed some core drug
patterns of prestigious clinicians in treatment of insom-
nia [15,16]. But these previous studies have some
shortcomings. On the one hand, the studies are retro-
spective and the data were collected from daily actual
clinical treatment information of prestigious clinicians.
In this case, the data quality cannot be guaranteed. On
the other hand, the treatment efficacy of prestigious
clinicians was not validated and needed confirmation in
further study. This study aims to screen the effective
core drug patterns of prestigious Chinese clinicians in
treatment of primary insomnia.
Objectives
The objective of this study is to screen the effective core
drug patterns in primary insomnia treatment with Chinese




This is a triple-blind (with patients, clinicians, outcome
assessors blinded), randomized, placebo-controlled, parallelgroup clinical trial. Figure 1 shows the trial design and
Table 1 summarizes the timing of the trial.
Randomization
Three Chinese clinicians will diagnose and treat every
eligible patient individually. Every Chinese clinician will
provide CM patterns and the prescription according to
every patient’s disease condition. There will therefore be
three prescriptions from three Chinese clinicians for
every patient at every visit. At the first visit, patient will
equally be randomized to one of the following four
groups: medical group A, medical group B, medical group
C or placebo group. Patients in the CM groups will be
given one of three Chinese clinicians’ prescriptions.
Patients in the placebo group will be given the placebo
simulating the core drug patterns in the previous study. In
the whole study, the randomization of group assignment
only occurs at the first visit, and the randomization results
will be applied to the following visits. In other words, al-
though the patients have to be diagnosed by every clin-
ician for every visit, they always receive the drug
prescribed by the clinician who is distributed to them by
randomization at the first visit or they receive placebo.
Furthermore, in order to avoid the potential bias, every
patient’s order to visit three clinicians is randomized at
every visit, meaning that the visiting order in which one
patient visits the clinicians may be different every time. It
is worth mentioning that a web central randomization sys-
tem is employed to guarantee the quality.
Chinese medicine groups
After randomization, patients in the CM groups are to re-
ceive one of three Chinese clinicians’ prescriptions. Every
Chinese clinician diagnoses the patients and prescribes in-
dividually based on patients’ syndrome differentiation and
their own CM experiences. During the whole treatment,
Chinese clinicians can make necessary adjustment in their
medicinal prescription depending on the condition of the
disease. The prescriptions of Chinese clinicians are pure
Chinese herbs.
Placebo group
Patients in the placebo group will receive the dummy of
the core drug patterns obtained in a previous retrospect-
ive study. The previous core drug patterns include Fried
semen Ziziphi Spinosae, Tuckahoe, Preparation of
Polygala, Chinese Angelica root, Lotus heart, White
peony root, dried tangerine peel, acorus calamus, Coptis
chinensis, and Licorice health.
All CM is a herbal concentrate-granule, not a decoc-
tion. The herbal concentrate-granule, a product of high
quality that can be intensively produced on a large scale,
possesses many advantages, such as small dosage, easy
to use and good effectiveness in clinical application. The
Inclusion criteria:
  -diagnosed primary insomnia with DSM-IV-TR 
  -aged between 18 and 65 years 
  -the Spiegel score ≥ 18 
Exclusion criteria:
 -total sleep time<2 hours 
 -secondary insomnia 
 -SAS score ≥ 60, BDI score ≥ 8 
 - complicating with hypertension, diabetes, stroke, 
and coronary heart disease history 
 - having drug abuse history
 -pregnancy or preparing to pregnancy 
-participating in another clinical at the same time
Washout period (-1 week)
CM Clinician 1 CM Clinician 2 CM Clinician 3
CM Pattern 1 CM Pattern 2 CM Pattern 3
Prescription 1 Prescription 2 Prescription 3
Visit 1 (0 week)?
Yes No
Randomization Along the first 
randomization





Visit 6 (4th week 
after the last 
treatment)
Signed the consent form
Figure 1 Trial design.
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with mechanization. In China, the herbal concentrate-
granule is widely accepted [17].
The placebo medicine dummy is produced by the
Pharmacy Department of Guang’anmen Hospital, China
Academy of Chinese Medical Sciences. The placebo is also
a herbal concentrate-granule, and is similar to the true
CM concentrate-granule in the aspects of color, taste,smell and package. According to the theory of CM, the
prescriptions will probably be adjusted at different visits
based on the patient’s disease condition. To achieve better
blinding, four kinds of placebos with different tastes will
therefore be designed for different visits.
One bag of herbal concentrate-granule is taken two
times daily one and half hour after breakfast and dinner,
respectively.
Table 1 Calendar summary
Period Screening Washout Treatment Follow-up
Week(W) -1 W 0 W 1 W 2 W 3 W 4 W 4th week after the end of treatment
Inclusion and exclusion criteria ×
Informed consent ×
Demography ×
Past Medical history & treatment history ×
Spiegel Scale × ×
Self-rating Anxiety Scale × × ×
Beck Depression Inventory × × ×
Pittsburgh Sleep Quality Index × × × × × × ×
CM syndromes and signs × × × × × × ×
Sleep diary × × × × × ×
Prescription (include every herb and dose) × × × ×
Vital signs × × × × × ×
Adver event × × × × ×
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Inclusion criteria and exclusion criteria
Patients are eligible to participate if they are aged be-
tween 18 and 65 years, and meet the definition of in-
somnia from the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision, with
Spiegel scale >18. It is imperative that patients should
read and sign an informed consent form to participate in
the trial.
The following exclusion criteria are observed: total sleep
time <2 hours, secondary insomnia, Self-rating Anxiety
Scale score >60, Beck Depression Inventory score <8,
complicated with hypertension, diabetes, stroke, and cor-
onary heart disease, having drug abuse history, pregnancy
or preparing for pregnancy, and participating in another
clinical trial at the same time.
Recruitment/consent procedures
Patients are recruited by means of poster at clinic. The
patient screening is conducted by the specified clinician
who doesn’t participate in the study. If a patient meets
the study criteria, the clinician responsible for patient
screening will provide him or her with written informa-
tion, explaining the study in detail in an understandable
language, and obtain written consent if he or she agrees
to take part in the study. All patients’ informed consent
must be obtained. Any patient cannot be enrolled if she/
he refuses or shows significant distress.
The procedure of study
In the washout period, an eligible patient who has
signed informed consent will receive placebo for 1 week
(washout period) in order to eliminate the influence ofdrugs taken before the study. In the treatment period
lasting 4 weeks and including four visits, each of three
Chinese clinicians will independently provide a disease
pattern and prescription for every patient. Three
generated prescriptions will then be passed on to the
pharmacy. However, whether one patient receives one
of three prescriptions or placebo is dependent on the re-
sult of randomization that is conducted by the
authorized person using a central randomization system
at the first visit.
When a patient returns to the hospital once a week after
the first treatment, a professional clinician will conduct an
assessment on efficacy. The patient will then receive the
secondary treatment from three Chinese clinicians,
repeating the same procedure as the first one. The whole
study will last 9 weeks, including 1-week washout, 4-week
treatment, and follow-up happening at the 4th week after
the last treatment.
All three Chinese clinicians are experts on insomnia
in Prestigious Chinese Clinician Research Laboratory of
Guang’anmen Hospital, China Academy of Chinese
Medical Sciences. In order to minimize potential bias
and to keep the blind condition of study as possible as
one can, all researchers participating in the study are
divided into three groups: clinical study group, diagnosis
and assessment group, and quality control and statistical
analysis group. In the quality control group, there are
two persons (the corresponding authors) are responsible
for the management and early stopping of the trial. A
clinical research data capture computer system is ap-
plied to collect the data in this study.
The study was approved by the Institutional Review
Board of the Institute of Basic Research in Clinical
Medicine, China Academy of Chinese Medical Sciences.
The approval number is 2011NO6.
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The investigator carrying out the efficacy assessment will
be blinded to which treatment the patients received. The
visits and assessments will take place at screening, wash-
out period, weeks 1, 2, 3, 4 after treatment, and the 4th
week after the last treatment. All assessments will be
conducted by the clinicians of the diagnosis and assess-
ment group.
Primary efficacy indicator
Total Sleep Time (TST)
In this study, the major indicator is the total sleep time
(TST), which is assessed according to the sleep diary. All
patients are required to record their sleeping informa-
tion in detail every day. The sleep diary contains the
following information: the time a patient goes to bed
and gets out of bed; the time a patient thinks sleep onset
occurs; the presumed cause, number, time, and length of
any nighttime awakenings and activities during these
moments; the name, dosage and time of any drugs used,
including medication, sleep aids, caffeine and alcohol,
and so forth; and activities happening 3 hours before
bedtime, such as meditation, watching television, playing
PC games, exercise, and so forth.
The efficacy can be confirmed only when improve-
ment in TST is >0.5 hours and is considered statistically
significant. Normally, the participants are not allowed to
take any pharmacologic medicine used to treat insomnia.
However, they are allowed to do so if they could not
bear the bitterness brought about by insomnia. Under
such circumstances, the dosage and the name of the
medicine must be recorded carefully in sleep diaries.
Secondary efficacy indicators
The secondary efficacy indicators include sleep onset
latency, wake time after sleep onset, sleep efficiency,
Pittsburgh sleep quality index (PSQI) and CM symptoms
and signs. Sleep onset latency, wake time after sleep
onset and sleep efficiency are obtained from the sleep
diary. The Chinese-version PSQI is employed to measure
the quality of sleep. The PSQI is a self-rated question-
naire used to assess sleep quality and disturbances over
a 1-month time interval. Nineteen individual items gen-
erate seven component scores: subjective sleep quality,
sleep latency, sleep duration, habitual sleep efficiency,
sleep disturbances, use of sleeping medication, and day-
time dysfunction.
Many studies have demonstrated that the Chinese-
version PSQI is a sensitive, reliable, and valid tool to assess
the quality of sleep [18,19]. In addition, CM symptoms
and signs will be assessed. The main symptoms and signs
include headache, dizziness, spontaneous sweating, night
sweating, dreaminess, amnesia, anorexia, lassitude of spirit
and lack of strength, oppression in the chest, daytimesleepiness, irritability, palpitations, epigastric fullness, tin-
nitus, thirst, bitter taste in the mouth, abundant sputum,
yellow urine, dry stool, sloppy stool, pulse condition, and
tongue manifestation.
Safety
Safety assessments will be based on adverse event
reports and vital signs. At every visit, adverse events and
vital signs will be recorded. The major indicators for
vital signs include breath, temperature, systolic blood
pressure, diastolic pressure, pulse, and so on. Generally,
any unexpected symptom, vital sign or sickness, as long
as they cause discomfort, shall be recorded as an adverse
event. The starting date, the ending date, the degree, the
relations with the trial medicine, and whether they drop
out of the study should be recorded correspondingly. If
necessary, the patients will receive relevant treatment. If
the adverse event still exists, the follow-up will go on
until the adverse event disappears.
Statistical methods
Sample size
The study is supposed to explore the daily clinical prac-
tice of three prestigious Chinese clinicians in primary in-
somnia treatment and to figure out the effective drug
patterns prescribed by them. However, it is very difficult
to estimate the sample size because of lack of a previous
relevant study. To obtain expected results with a min-
imal sample size, a sequential design will be employed.
The interim analysis will be conducted when the total
number of patients having completed the study reaches
80 and 160 separately, for which we set up the early
stopping criteria. The interim study can be treated as
final if the difference in TST changes from baseline at 4
weeks between the CM and placebo groups is >0.5 hours
and has statistical significance with P <0.05. When the
early stopping criteria are met, the placebo group and
the non-effective group will be dropped. The subsequent
study will only focus on the effective group to explore the
core drug patterns. If the number of effective patients is
not sufficient to determine the core drug patterns, the re-
cruitment procedure has to continue. The core drug pat-
tern analysis shall be carried out every time the increment
of new enrollment reaches 30 until the core drug patterns
are obtained and kept constant.
Analysis strategy
The analysis will be per intent to treat. The mean and
standard deviation shall be applied to the continuous
variables, and percentages to the categorical variables.
For comparison of two independent samples, the t test
and analysis of variance will be applied for continuous
variables and the chi-square test for categorical variables.
In addition, nonparametric tests will also be applied for
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logic medicine will be assessed using the method of last
observation carried forward.
As mentioned above, the exploration analysis on core
drug patterns will only be based on the effective patients
in order to guarantee the efficacy of the explored core pre-
scription. The patients’ syndrome and signs, CM patterns
and the treatment effect shall be considered during the
analysis. The core drug pattern can be concluded from the
combination of high correlation and frequency. The core
drug patterns must confirm to the CM theory and be
accepted by the prestigious Chinese clinicians. The multi-
dimension association rule and scale-free networks
method will be applied to mine the core drug patterns
and drug utilization rule of three Chinese clinicians
[15,20-22]. In CM, the disease syndromes and signs, dis-
ease pattern and treatment are a dynamic procedure. The
disease pattern varies with syndromes and signs. As a re-
sult, the treatment varies with the pattern of disease. So
we not only explore the core drug patterns of different
prestigious Chinese clinicians, but also mine the core
drug patterns corresponding to different syndrome combi-
nations and disease patterns.
Discussion
The discovery of a new effective prescription in clinical
practice is key to the development of new CM. The
experiences of prestigious Chinese clinicians are the main
source of effective CM. However, the discovery of effective
core drug patterns mainly depends on the accumulation
of clinicians’ experiences and is always a long process.
This study proposes one method used to develop new ef-
fective core drug patterns based on the prestigious
clinicians’ treatment data. Randomization, placebo control
and blinding designs are employed in the study, where
three prestigious Chinese clinicians are treated as subjects.
To minimize the bias and factitious influence, a web cen-
tral randomization system and a clinical research data-
capture computer system are adopted to assign the group
and collect the data, respectively. In the study, we can ob-
tain one or several effective core drug patterns. Unlike
previous retrospective studies [15,16], this perspective
study has strictly tested the efficacy of Chinese herbal
medicine through comparison between a treatment group
and a placebo group. Because the exploratory analysis of
core drug patterns is based on the effective patients, the
results should be more accurate and useful. In a word, the
analysis can accelerate and improve the development of
new Chinese herbal medicine for discovery of new effect-
ive core drug patterns through exploring the treatment
data of prestigious CM clinicians.
To guarantee the quality of the study and accuracy of
core herb patterns obtained, patients who met the diagno-
sis of primary insomnia were recruited. In addition, thosepatients with hypertension, diabetes, stroke and coronary
heart diseases are excluded because these patients may
demonstrate mixed symptoms or syndromes in the diag-
nosis that affect the accuracy of prescriptions by clinicians.
Patients older than 65 are easily complicated with the
diseases mentioned above and then excluded from the
study.
In Chinese medical treatment, different Chinese clini-
cians possess different ideas on diagnosis and treatment.
One or more than one core prescriptions could therefore
possibly be obtained. In this case, the question is raised
about whether the explored core prescription can be
generalized from this relatively small group. On one hand,
the three Chinese clinicians are experts in this field and
can represent the best in China. As a result, their
prescriptions could be treated as valuable. On the other
hand, in the study the clinicians are actually considered as
treatment instead of as sample. Hence, there should not
be a problem of small size for clinicians. Nevertheless, fur-
ther randomized controlled trial study will be done to
examine the efficacy of the core prescription.
There is another factor that needs to be explained – that
the primary outcome TST is from a sleep diary but
not from an objective measure (polysomnographic or
actigraphy). TST from a sleep diary by patient self-
reporting has been efficiently used in most of the treat-
ment studies on insomnia. Although it is subjective and
there is often a divergence compared with objective sleep
measures, we think it is acceptable because our study is an
exploratory study and in clinical practice many patients
with insomnia do not receive overnight sleep monitoring.
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